The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors

• DOI: 10.3389/fphar.2022.910722
• Publication Date: 2022-10-18T06:25:21Z
• Authors: Wen Kou; Yan Yan Lin; Fei Su; Yue Xiang; Hui Qiao; Xin’An Wu; Xiao-Ming Hou
• Keywords: Discontinuation; Pharmaceutical Care

Background: Immune checkpoint inhibitors combined chemotherapy (ICIC) are widely used for various types of lung cancer in the past decade. However, ICIC related adverse events (AEs) more serious than immune-related (irAE) or cytotoxic alone. Objective: This prospective interventional study aimed to evaluate impact pharmaceutical care program reducing and analyze pharmacy interventions patients with NSCLC who receive therapies. Method: were enrolled this study, was introduced after received second cycle therapies, followed by pharmacist 6 months hospital discharge. The percentages between first two cycles analyzed compared. Results: After treatment cycles, clinical proposed 67 30 patients. most frequent intervention drug discontinuation (40.3%, 27/67) modification (14.9%, 10/67). There significant decreases AEs respect nausea (≥grade-2, 14% vs. 28.3%, p = 0.039), constipation 8.8% 21.7%, diarrhea 6% 16.7%, 0.031), myelosuppression 15.8% 30.0%, 0.022). Conclusion: Provision receiving therapies can optimize therapy reduce events.